These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 21805478)

  • 1. Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents.
    Uboldi S; Bernasconi S; Romano M; Marchini S; Fuso Nerini I; Damia G; Ganzinelli M; Marangon E; Sala F; Clivio L; Chiorino G; Di Giandomenico S; Rocchi M; Capozzi O; Margison GP; Watson AJ; Caccuri AM; Pastore A; Fossati A; Mantovani R; Grosso F; Tercero JC; Erba E; D'Incalci M
    Int J Cancer; 2012 Jul; 131(1):59-69. PubMed ID: 21805478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors.
    Forni C; Minuzzo M; Virdis E; Tamborini E; Simone M; Tavecchio M; Erba E; Grosso F; Gronchi A; Aman P; Casali P; D'Incalci M; Pilotti S; Mantovani R
    Mol Cancer Ther; 2009 Feb; 8(2):449-57. PubMed ID: 19190116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mode of action of trabectedin in myxoid liposarcomas.
    Di Giandomenico S; Frapolli R; Bello E; Uboldi S; Licandro SA; Marchini S; Beltrame L; Brich S; Mauro V; Tamborini E; Pilotti S; Casali PG; Grosso F; Sanfilippo R; Gronchi A; Mantovani R; Gatta R; Galmarini CM; Sousa-Faro JM; D'Incalci M
    Oncogene; 2014 Oct; 33(44):5201-10. PubMed ID: 24213580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.
    Germano G; Frapolli R; Simone M; Tavecchio M; Erba E; Pesce S; Pasqualini F; Grosso F; Sanfilippo R; Casali PG; Gronchi A; Virdis E; Tarantino E; Pilotti S; Greco A; Nebuloni M; Galmarini CM; Tercero JC; Mantovani A; D'Incalci M; Allavena P
    Cancer Res; 2010 Mar; 70(6):2235-44. PubMed ID: 20215499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systems biology approach to characterize the regulatory networks leading to trabectedin resistance in an in vitro model of myxoid liposarcoma.
    Uboldi S; Calura E; Beltrame L; Fuso Nerini I; Marchini S; Cavalieri D; Erba E; Chiorino G; Ostano P; D'Angelo D; D'Incalci M; Romualdi C
    PLoS One; 2012; 7(4):e35423. PubMed ID: 22523595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nuclear expression of FLT1 and its ligand PGF in FUS-DDIT3 carrying myxoid liposarcomas suggests the existence of an intracrine signaling loop.
    Andersson MK; Göransson M; Olofsson A; Andersson C; Aman P
    BMC Cancer; 2010 Jun; 10():249. PubMed ID: 20515481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FUS-CHOP Promotes Invasion in Myxoid Liposarcoma through a SRC/FAK/RHO/ROCK-Dependent Pathway.
    Tornin J; Hermida-Prado F; Padda RS; Gonzalez MV; Alvarez-Fernandez C; Rey V; Martinez-Cruzado L; Estupiñan O; Menendez ST; Fernandez-Nevado L; Astudillo A; Rodrigo JP; Lucien F; Kim Y; Leong HS; Garcia-Pedrero JM; Rodriguez R
    Neoplasia; 2018 Jan; 20(1):44-56. PubMed ID: 29190494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel models of myxoid liposarcoma xenografts mimicking the biological and pharmacologic features of human tumors.
    Frapolli R; Tamborini E; Virdis E; Bello E; Tarantino E; Marchini S; Grosso F; Sanfilippo R; Gronchi A; Tercero JC; Peloso G; Casali P; Pilotti S; D'Incalci M
    Clin Cancer Res; 2010 Oct; 16(20):4958-67. PubMed ID: 20732964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The myxoid liposarcoma FUS-DDIT3 fusion oncoprotein deregulates NF-kappaB target genes by interaction with NFKBIZ.
    Göransson M; Andersson MK; Forni C; Ståhlberg A; Andersson C; Olofsson A; Mantovani R; Aman P
    Oncogene; 2009 Jan; 28(2):270-8. PubMed ID: 18850010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myxoid liposarcoma FUS-DDIT3 fusion oncogene induces C/EBP beta-mediated interleukin 6 expression.
    Göransson M; Elias E; Ståhlberg A; Olofsson A; Andersson C; Aman P
    Int J Cancer; 2005 Jul; 115(4):556-60. PubMed ID: 15688424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression.
    Perazzoli G; Prados J; Ortiz R; Caba O; Cabeza L; Berdasco M; Gónzalez B; Melguizo C
    PLoS One; 2015; 10(10):e0140131. PubMed ID: 26447477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiangiogenic activity of trabectedin in myxoid liposarcoma: involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1.
    Dossi R; Frapolli R; Di Giandomenico S; Paracchini L; Bozzi F; Brich S; Castiglioni V; Borsotti P; Belotti D; Uboldi S; Sanfilippo R; Erba E; Giavazzi R; Marchini S; Pilotti S; D'Incalci M; Taraboletti G
    Int J Cancer; 2015 Feb; 136(3):721-9. PubMed ID: 24917554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A mechanistic study on the metastasis inducing function of FUS-CHOP fusion protein in liposarcoma.
    Patil N; Ahmed Kabeer Rasheed S; Abba M; Hendrik Leupold J; Schwarzbach M; Allgayer H
    Int J Cancer; 2014 Jun; 134(12):2808-19. PubMed ID: 24285420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TLS-CHOP represses miR-486 expression, inducing upregulation of a metastasis regulator PAI-1 in human myxoid liposarcoma.
    Borjigin N; Ohno S; Wu W; Tanaka M; Suzuki R; Fujita K; Takanashi M; Oikawa K; Goto T; Motoi T; Kosaka T; Yamamoto K; Kuroda M
    Biochem Biophys Res Commun; 2012 Oct; 427(2):355-60. PubMed ID: 22995304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel oncogenic pathway by TLS-CHOP involving repression of MDA-7/IL-24 expression.
    Oikawa K; Tanaka M; Itoh S; Takanashi M; Ozaki T; Muragaki Y; Kuroda M
    Br J Cancer; 2012 Jun; 106(12):1976-9. PubMed ID: 22588557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of FUS-CHOP in Myxoid Liposarcoma via miR-486/CDK4 Axis.
    Wu H; Xia L; Xu H
    Biochem Genet; 2022 Jun; 60(3):1095-1106. PubMed ID: 34792704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of the FUS-CHOP fusion protein in primary mesenchymal progenitor cells gives rise to a model of myxoid liposarcoma.
    Riggi N; Cironi L; Provero P; Suvà ML; Stehle JC; Baumer K; Guillou L; Stamenkovic I
    Cancer Res; 2006 Jul; 66(14):7016-23. PubMed ID: 16849546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study.
    Grosso F; Jones RL; Demetri GD; Judson IR; Blay JY; Le Cesne A; Sanfilippo R; Casieri P; Collini P; Dileo P; Spreafico C; Stacchiotti S; Tamborini E; Tercero JC; Jimeno J; D'Incalci M; Gronchi A; Fletcher JA; Pilotti S; Casali PG
    Lancet Oncol; 2007 Jul; 8(7):595-602. PubMed ID: 17586092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PPARγ agonists enhance ET-743-induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma.
    Charytonowicz E; Terry M; Coakley K; Telis L; Remotti F; Cordon-Cardo C; Taub RN; Matushansky I
    J Clin Invest; 2012 Mar; 122(3):886-98. PubMed ID: 22293175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trabectedin, a drug acting on both cancer cells and the tumour microenvironment.
    D'Incalci M; Badri N; Galmarini CM; Allavena P
    Br J Cancer; 2014 Aug; 111(4):646-50. PubMed ID: 24755886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.